Why Did UPB Stock Pop 20% In Pre-Market Today?
Synopsis
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.
Shares of Upstream Bio Inc. (UPB) surged nearly 20% in pre-market trading on Wednesday after the company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.
Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function.
Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment’s durability.
Read updates to this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.